tiprankstipranks
Tvardi Therapeutics (TVRD)
NASDAQ:TVRD
US Market
Want to see TVRD full AI Analyst Report?

Tvardi Therapeutics (TVRD) Stock Forecast & Price Target

2,520 Followers
See the Price Targets and Ratings of:

TVRD Analyst Ratings

Moderate Buy
6Ratings
Moderate Buy
3 Buy
2 Hold
1 Sell
Based on 6 analysts giving stock ratings to
Tvardi
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TVRD Stock 12 Month Forecast

Average Price Target

$8.60
▲(153.69% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Tvardi Therapeutics in the last 3 months. The average price target is $8.60 with a high forecast of $15.00 and a low forecast of $3.00. The average price target represents a 153.69% change from the last price of $3.39.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","11":"$11","20":"$20","29":"$29","38":"$38"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,11,20,29,38],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.14,4.052307692307693,4.964615384615385,5.876923076923077,6.78923076923077,7.701538461538462,8.613846153846154,9.526153846153846,10.438461538461539,11.350769230769231,12.263076923076923,13.175384615384615,14.087692307692308,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.14,3.56,3.98,4.4,4.82,5.24,5.66,6.08,6.5,6.92,7.34,7.76,8.18,{"y":8.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.14,3.1292307692307695,3.1184615384615384,3.1076923076923078,3.096923076923077,3.086153846153846,3.0753846153846154,3.0646153846153847,3.053846153846154,3.043076923076923,3.0323076923076924,3.0215384615384617,3.0107692307692306,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.755,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.58,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.82,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.65,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.91,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.3,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.99,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.14,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$15.00Average Price Target$8.60Lowest Price Target$3.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
JonesTrading
$12
Buy
253.98%
Upside
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Tvardi Therapeutics (NASDAQ: TVRD) and Organigram Global (NASDAQ: OGI)
Oppenheimer Analyst forecast on TVRD
Unknown Analyst
Oppenheimer
Not Ranked
Oppenheimer
$10
Buy
194.99%
Upside
Reiterated
05/11/26
Oppenheimer Sticks to Its Buy Rating for Tvardi Therapeutics (TVRD)
Cantor Fitzgerald Analyst forecast on TVRD
Unknown Analyst
Cantor Fitzgerald
Not Ranked
Cantor Fitzgerald
Hold
Reiterated
05/11/26
Cantor Fitzgerald Sticks to Their Hold Rating for Tvardi Therapeutics (TVRD)
BTIG
$15
Buy
342.48%
Upside
Reiterated
05/08/26
Tvardi Therapeutics (TVRD) Receives a Buy from BTIG
Barclays Analyst forecast on TVRD
Barclays
Barclays
$3
Sell
-11.50%
Downside
Assigned
05/08/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Impedimed Limited (Other OTC: IPDQF), Eli Lilly & Co (NYSE: LLY) and Tvardi Therapeutics (NASDAQ: TVRD)
Piper Sandler Analyst forecast on TVRD
Piper Sandler
Piper Sandler
$4$3
Hold
-11.50%
Downside
Reiterated
04/01/26
Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (NASDAQ: TVRD) and Forte Biosciences (NASDAQ: FBRX)
Lucid Capital Analyst forecast on TVRD
Lucid Capital
Lucid Capital
$6
Buy
76.99%
Upside
Upgraded
02/04/26
Tvardi Therapeutics upgraded to Buy from Neutral at Lucid CapitalTvardi Therapeutics upgraded to Buy from Neutral at Lucid Capital
Raymond James Analyst forecast on TVRD
Raymond James
Raymond James
Hold
Downgraded
10/14/25
Tvardi downgraded to Market Perform from Outperform at Raymond JamesTvardi downgraded to Market Perform from Outperform at Raymond James
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
JonesTrading
$12
Buy
253.98%
Upside
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Tvardi Therapeutics (NASDAQ: TVRD) and Organigram Global (NASDAQ: OGI)
Oppenheimer Analyst forecast on TVRD
Unknown Analyst
Oppenheimer
Not Ranked
Oppenheimer
$10
Buy
194.99%
Upside
Reiterated
05/11/26
Oppenheimer Sticks to Its Buy Rating for Tvardi Therapeutics (TVRD)
Cantor Fitzgerald Analyst forecast on TVRD
Unknown Analyst
Cantor Fitzgerald
Not Ranked
Cantor Fitzgerald
Hold
Reiterated
05/11/26
Cantor Fitzgerald Sticks to Their Hold Rating for Tvardi Therapeutics (TVRD)
BTIG
$15
Buy
342.48%
Upside
Reiterated
05/08/26
Tvardi Therapeutics (TVRD) Receives a Buy from BTIG
Barclays Analyst forecast on TVRD
Barclays
Barclays
$3
Sell
-11.50%
Downside
Assigned
05/08/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Impedimed Limited (Other OTC: IPDQF), Eli Lilly & Co (NYSE: LLY) and Tvardi Therapeutics (NASDAQ: TVRD)
Piper Sandler Analyst forecast on TVRD
Piper Sandler
Piper Sandler
$4$3
Hold
-11.50%
Downside
Reiterated
04/01/26
Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (NASDAQ: TVRD) and Forte Biosciences (NASDAQ: FBRX)
Lucid Capital Analyst forecast on TVRD
Lucid Capital
Lucid Capital
$6
Buy
76.99%
Upside
Upgraded
02/04/26
Tvardi Therapeutics upgraded to Buy from Neutral at Lucid CapitalTvardi Therapeutics upgraded to Buy from Neutral at Lucid Capital
Raymond James Analyst forecast on TVRD
Raymond James
Raymond James
Hold
Downgraded
10/14/25
Tvardi downgraded to Market Perform from Outperform at Raymond JamesTvardi downgraded to Market Perform from Outperform at Raymond James
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Tvardi Therapeutics

3 Months
Success Rate
5/9 ratings generated profit
56%
Average Return
-3.24%
Copying Debanjana Chatterjee's trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of -3.24% per trade.
1 Year
Success Rate
4/9 ratings generated profit
44%
Average Return
-36.30%
Copying Debanjana Chatterjee's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -36.30% per trade.
2 Years
Success Rate
4/9 ratings generated profit
44%
Average Return
-35.73%
Copying Debanjana Chatterjee's trades and holding each position for 2 Years would result in 44.44% of your transactions generating a profit, with an average return of -35.73% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TVRD Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
5
6
6
6
6
Buy
0
0
0
0
0
Hold
3
0
0
3
4
Sell
0
0
0
1
2
Strong Sell
0
0
0
0
0
total
8
6
6
10
12
In the current month, TVRD has received 6 Buy Ratings, 4 Hold Ratings, and 2 Sell Ratings. TVRD average Analyst price target in the past 3 months is 8.60.
Each month's total comprises the sum of three months' worth of ratings.

TVRD Financial Forecast

TVRD Earnings Forecast

Next quarter’s earnings estimate for TVRD is -$0.69 with a range of -$1.17 to -$0.41. The previous quarter’s EPS was ―. TVRD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year TVRD has Performed in-line its overall industry.
Next quarter’s earnings estimate for TVRD is -$0.69 with a range of -$1.17 to -$0.41. The previous quarter’s EPS was ―. TVRD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year TVRD has Performed in-line its overall industry.

TVRD Sales Forecast

Next quarter’s sales forecast for TVRD is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were ―. TVRD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year TVRD has Performed in-line its overall industry.
Next quarter’s sales forecast for TVRD is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were ―. TVRD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year TVRD has Performed in-line its overall industry.

TVRD Stock Forecast FAQ

What is TVRD’s average 12-month price target, according to analysts?
Based on analyst ratings, Tvardi Therapeutics’s 12-month average price target is 8.60.
    What is TVRD’s upside potential, based on the analysts’ average price target?
    Tvardi Therapeutics has 153.69% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is TVRD a Buy, Sell or Hold?
          Tvardi Therapeutics has a consensus rating of Moderate Buy which is based on 3 buy ratings, 2 hold ratings and 1 sell ratings.
            What is Tvardi Therapeutics’s price target?
            The average price target for Tvardi Therapeutics is 8.60. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $15.00 ,the lowest forecast is $3.00. The average price target represents 153.69% Increase from the current price of $3.39.
              What do analysts say about Tvardi Therapeutics?
              Tvardi Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of TVRD?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.